Learning Objective To describe thrombosis of sirolimus-coated mesenteric arterial stents following cessation of clopidogrel therapy.
Background Cardiac drug-eluting stent thrombosis following cessation of antiplatelet therapy with clopidogrel has been associated with increased mortality. The application of such stents in the mesenteric arterial system and the subsequent need for clopidogrel therapy has not been studied. This is the first case report of acute thrombosis of a drug-coated stent in the mesenteric circulation.
Clinical Findings Acute mesenteric ischemia secondary to thrombosis of a mesenteric arterial stent following clopidogrel cessation is described.
Conclusion Drug-eluting stents represent an option for mesenteric revascularization in the surgically complicated abdomen. As in the setting of cardiac stenting, acute thrombosis of these devices following cessation of clopidogrel therapy is a concern. Indefinite clopidogrel therapy following deployment of drug-coated stents should be considered.
Vedantham S. , Picus D., Sanchez L., et al. Percutaneous management of ischemic complications in patients with type-B aortic dissection. J Vasc Interv Radiol.2003;14: 181-194.
2.
Slonim S., Miller D., Mitchell R., Semba CP, Razavi MK, Dake MDPercutaneous balloon fenestration and stenting for life threatening ischemic complications in patients with acute aortic dissection. J Thoac Cardiovasc Surg.1999;117:1119-1127.
3.
Leprince P., Cluzel P., Bonnet N., Izzillo R., Pavie A., Gandjbakhch I.An endovascular stent relieves celiac and mesenteric ischemia in acute aortic dissection. Ann Thorac Surg.2004;78:e3-e5.
4.
Park W., Gloviczki P., Cherry KJJr, et al. Contemporary management of acute mesenteric ischemia: Factors associated with survival. J Vasc Surg.2002 ;35:445-452.
5.
Brountzos E., Critselis A., Magoulas D., Kagianni E., Kelekis DAEmergency endovascular treatment of a superior mesenteric artery occlusion . Cardiovasc Intervent Radiol.2001;24:57-60.
6.
Leung D., Schneider E., Kubik-Huch R., Marincek B., Pfammatter T.Acute mesenteric artery ischemia caused by spontaneous isolated dissection of the superior mesenteric artery: treatment by percutaneous stent placement . Eur Radiol.2000;10:1916-1919.
7.
Freeman A., Graham J.Damage control surgery and angiography in cases of acute mesenteric ischaemia. ANZJ Surg.2005;75:308-314.
8.
Lim R., Dowling R., Mitchell P., Vrazas JI, Thomson KR, Tress BMEndovascular treatment of arterial mesenteric ischaemia: a retrospective review . Australas Radiol.2005;49:467-475.
9.
Kutlu R., Ara C., Sarac K.Bare stent implantation in iatrogenic dissecting pseudoaneurysm of the superior mesenteric artery. Cardiovasc Intervent Radiol.2007;30: 121-123.
10.
Pfisterer M. , Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidigrel discontinuation may limit benefit of drug eluting stents: an observational study of drug-eluting versus bare metal stents . J Am Coll Cardiol. 2006;48:2584-2591.
11.
Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DLLate thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med.2006;119:1056-1061.
12.
FDA Statement on Coronary Drug-Eluting Stents, 2006. Available at: http://www.fda.gov/cdrh/news/091406.html.
13.
Collet JP, Montalescot G., Blanchet B., et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes. Circulation. 2004;110: 2361-2367.
14.
Mehta SR, Yusuf S., Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing coronary percutaneous intervention: the PCI-CURE study. Lancet. 2001;358: 527-533.
Batellier J. , Kieny R.Superior mesenteric artery embolism: eighty-two cases. Ann Vasc Surg.1990;4:112-116.
17.
Ottinger L.The surgical management of acute occlusion of the superior mesenteric artery. Ann Surg.1978;188: 721-731.
18.
Wilson C., Gupta R., Gilmour D., Imrie CWAcute superior mesenteric ischaemia. Br J Surg.1987;74:279-281.
19.
US Food and Drug Administration.CYPHER sirolimus-eluting coronary stent on raptor over-the-wire delivery system or RAPTORRAIL rapid exchange delivery system-P020026. Available at: http//www.fda.gov/cdrh/PDF2/P020026.html. Accessed January 19, 2007.
20.
US Food and Drug Administration.TAXUS Express 2 paclitaxel-eluting coronary stent system (monorail and over the wire)-P030025. Available at: http//www.fda.gov/cdrh/PDF3/P020026.html. Accessed January 19, 2007.
21.
Stone G., Ellis S., Cox D., et al. A polymer-based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med.2004;350:221-231.
22.
Morice M., Serruys P., Sousa J., et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med.2002;346: 1773-1780.
23.
Moses J., Leon M., Pompa J., et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Eng J Med.2003;349: 1315-1323.
24.
Kastrati A. , Mehilli J., von Beckerath N., et al. Sirolimus-eluting stent or paxclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA. 2005;293:165-171.
25.
Ardissino D. , Cavallini C., Bramucci E., et al. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial . JAMA.2004;292:2727-2734.
